Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-MSCs for Sweat Gland Regeneration
NCT02304562Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2013
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Promostem in burn injury and sweat gland diseases, sponsored by Chinese PLA General Hospital. Primary endpoint: Frequency of Adverse Events at 6 months. Status: unknown.
02
Drugs
Promostem
03
Conditions
burn injurysweat gland diseases
Beyond the preview
Go deeper on NCT02304562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304562.